Lillian L. Siu - Concepedia

Author

Lillian L. Siu

Also Known As

Alice T. Shaw, David Sher, Girish Putcha, Hitesh B. Singh, Hotte, Sebastien, L L Siu, L Siu, L. L. Siu, L. Siu, L.L. SIU

1.3K

Publications

40.3K

Citations

100

H-Index

180

Concepts

All Affiliations

Princess Margaret Cancer Centre University of Toronto University Health Network Ontario Institute for Cancer Research National Cancer Institute

About

Lillian L. Siu is an author at Princess Margaret Cancer Centre specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	57	153	12.2K
2	Health Sciences	24	37	3.1K
3	Engineering	6	6	347
4	Public Health	5	5	355
5	Nursing	1	1	28

Lillian L. Siu

321

Publications

29.2K

Citations

H-Index

Page 1

	Year	Citations
AACR Project GENIE: Powering Precision Medicine through an International Consortium Fabrice André, Mónica Arnedos, Alexander S. Baras, Cancer Discovery	2017	1.9K
Tumour heterogeneity in the clinic Philippe L. Bédard, Aaron R. Hansen, Mark J. Ratain, Nature Neuro-oncologyTumoral PathologyTumor HeterogeneityMedicineHistopathology	2013	1.2K
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Manuel Hidalgo, Lillian L. Siu, John Nemunaitis, Journal of Clinical Oncology	2001	997
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Denis Soulières, Neil Senzer, Everett E. Vokes, Journal of Clinical Oncology	2003	803
Toward understanding and exploiting tumor heterogeneity Ash A. Alizadeh, Victoria Aranda, Alberto Bardelli, Nature Medicine Tumor HeterogeneityCancer GenomicsMedicineRadiation OncologyCancer Research	2015	749
The statins as anticancer agents. Kelvin Chan, Amit M. Oza, Lillian L. Siu PubMed Chemoprevention StrategyPharmacotherapyAnticancer AgentsTumor BiologyInflammation	2003	604
Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis Brian O’Sullivan, Shao Hui Huang, Lillian L. Siu, Journal of Clinical Oncology	2013	585
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab Scott V. Bratman, S.Y. Cindy Yang, Marco Iafolla, Nature Cancer Prognostic BiomarkersTumor Dna AnalysisMedicineBiomarker TargetImmunology	2020	466
Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group Anne W.M. Lee, W.H. Lau, Stewart Y. Tung, Journal of Clinical Oncology	2005	444
Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus–Related Oropharyngeal Carcinomas Shao Hui Huang, Wei Xu, John Waldron, Journal of Clinical Oncology	2015	395

Page 1